With over 250 investigators, the II-ON has
undertaken more than 150 research projects across 20 tumor types
including 12 clinical trials since its launch in 2012
Global collaboration now includes 15 leading
academic institutions
Bristol-Myers Squibb Company (NYSE:BMY) today announced that
Columbia University Medical Center and Peter MacCallum Cancer
Centre (Peter Mac) have joined the International Immuno-Oncology
Network (II-ON), a global peer-to-peer collaboration between
Bristol-Myers Squibb and academia that aims to advance
Immuno-Oncology (I-O) science and translational medicine to improve
patient outcomes. Launched in 2012 by Bristol-Myers Squibb, the
II-ON was one of the first networks to bring academia and industry
together to further the scientific understanding of I-O, and has
expanded from 10 to 15 sites including more than 250 investigators
working on over 150 projects across 20 tumor types. The II-ON has
generated cutting-edge I-O data that have informed the development
of new I-O agents, yielded publications and produced some of the
earliest findings on a variety of biomarkers and target
identification and validation.
“Bristol-Myers Squibb has long believed the future of cancer
research is dependent on investments in science and partnerships.
We formed the II-ON to facilitate innovation in I-O science and
drug discovery by providing a streamlined framework for
peer-to-peer collaboration among global cancer research leaders,”
said Nils Lonberg, Head of Oncology Biology Discovery at
Bristol-Myers Squibb. “The significant discoveries generated by the
II-ON over the past five years have not only informed our robust
early I-O pipeline, but also serve to advance the entire field. We
are proud to collaborate with Columbia University Medical Center
and Peter Mac, and together with the entire II-ON will continue to
lead pioneering research and heighten our collective understanding
of the science behind I-O.”
Through the II-ON, Bristol-Myers Squibb is collaborating with
leading cancer research institutions around the world to generate
innovative I-O science, launch biology-driven trials and seek out
cutting-edge technologies with the goal of translating research
findings into clinical trials and, ultimately, clinical
practice.
“I-O research may be transforming the way we treat cancer,” said
Charles G. Drake, MD, PhD, Professor of Medicine at Columbia
University Medical Center and Director of Genitourinary Oncology
and Associate Director for Clinical Research at the Herbert Irving
Comprehensive Cancer Center at New York-Presbyterian/Columbia. “The
II-ON offers a tremendous opportunity to work smarter and faster
along with our colleagues to address fundamental scientific
questions in I-O.”
“We believe the collective knowledge and research power of the
II-ON will generate groundbreaking findings in I-O with the
potential to improve outcomes for people affected by cancer,” said
Professor Joe Trapani, Executive Director Cancer Research and Head
of the Cancer Immunology Program at Peter MacCallum Cancer Centre,
Melbourne, Australia.
Building on the success of the II-ON, Bristol-Myers Squibb has
invested in several other models of scientific collaboration with
academic partners across the globe, including the Global Expert
Centers Initiative (GECI) and the Immuno-Oncology Integrated
Community Oncology Network (IO-ICON). "We believe a
one-size-fits-all research approach does not facilitate
innovation,” said Lonberg. “Our tailored collaborations with
academic centers expand our research capabilities and accelerate
our collective ability to deliver potentially life-changing results
for patients."
About the International Immuno-Oncology
Network (II-ON)
The II-ON, formed in 2012, is a global peer-to-peer
collaboration between Bristol-Myers Squibb and academia advancing
the science of Immuno-Oncology (I-O) through a series of
preclinical, translational and biology-focused research objectives.
The research in the collaboration is focused on three fundamental
scientific pillars: understanding the mechanisms of resistance to
immunotherapy; identifying patient populations likely to benefit
from immunotherapy; and exploring novel combination therapies that
may enhance anti-tumor response through complementary mechanisms of
action. The II-ON facilitates the translation of scientific
research findings into drug discovery and development, with the
goal of introducing new treatment options into clinical
practice.
In addition to Bristol-Myers Squibb, the II-ON currently
comprises 15 leading cancer research institutions, including:
Clinica Universidad Navarra, Dana-Farber Cancer Institute, The
Earle A. Chiles Research Institute (Providence Health &
Services), Institut Gustave Roussy, Istituto Nazionale per lo
Studio e la Cura dei Tumori “Fondazione G. Pascale”,
Bloomberg-Kimmel Institute for Cancer Immunotherapy at the Johns
Hopkins Kimmel Cancer Center, Memorial Sloan Kettering Cancer
Center, National Cancer Center Japan, The Netherlands Cancer
Institute, The Royal Marsden NHS Foundation
Trust and The Institute of Cancer Research, University
College London, The University of Chicago, West German Cancer
Center/University Hospital Essen, and now Columbia University
Medical Center and Peter MacCallum Cancer Centre.
Bristol-Myers Squibb: At the Forefront
of Immuno-Oncology Science & Innovation
At Bristol-Myers Squibb, patients are at the center of
everything we do. Our vision for the future of cancer care is
focused on researching and developing transformational
Immuno-Oncology (I-O) medicines that will raise survival
expectations in hard-to-treat cancers and will change the way
patients live with cancer.
We are leading the scientific understanding of I-O through our
extensive portfolio of investigational and approved agents –
including the first combination of two I-O agents in metastatic
melanoma – and our differentiated clinical development program,
which is studying broad patient populations across more than 20
types of cancers with 12 clinical-stage molecules designed to
target different immune system pathways. Our deep expertise and
innovative clinical trial designs uniquely position us to advance
the science of combinations across multiple tumors and potentially
deliver the next wave of I-O combination regimens with a sense of
urgency. We also continue to pioneer research that will help
facilitate a deeper understanding of the role of immune biomarkers
and inform which patients will benefit most from I-O therapies.
We understand making the promise of I-O a reality for the many
patients who may benefit from these therapies requires not only
innovation on our part, but also close collaboration with leading
experts in the field. Our partnerships with academia, government,
advocacy and biotech companies support our collective goal of
providing new treatment options to advance the standards of
clinical practice.
About Bristol-Myers
Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit us
at BMS.com or follow us on
LinkedIn, Twitter, YouTube and Facebook.
Bristol-Myers Squibb Forward-Looking Statement
This press release contains “forward-looking statements” as that
term is defined in the Private Securities Litigation Reform Act of
1995 regarding the research, development and commercialization of
pharmaceutical products. Such forward-looking statements are based
on current expectations and involve inherent risks and
uncertainties, including factors that could delay, divert or change
any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking statement
can be guaranteed. Forward-looking statements in this press release
should be evaluated together with the many uncertainties that
affect Bristol-Myers Squibb’s business, particularly those
identified in the cautionary factors discussion in Bristol-Myers
Squibb’s Annual Report on Form 10-K for the year ended December 31,
2016 in our Quarterly Reports on Form 10-Q and our Current Reports
on Form 8-K. Bristol-Myers Squibb undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170227005401/en/
Bristol-Myers SquibbMedia:Sarah Koenig,
609-252-4145sarah.koenig@bms.comorInvestors:Tim Power,
609-252-7509timothy.power@bms.comorBill Szablewski,
609-252-5894william.szablewski@bms.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024